Retina360: Advances in the Management of Retinal Diseases; Volume 1, Number 4

1.25 CME
1.25 ABO MOC
$0 FEE
Retina360: Advances in the Management of Retinal Diseases; Volume 1, Number 4


Provider Statement

This continuing medical education activity is provided by Vindico Medical Education.

Support Statement

This activity is supported by independent medical education grants from Genentech, Inc.; Novartis Pharmaceuticals Corporation; and Regeneron Pharmaceuticals, Inc.

Activity Description

The continued refinement of treatment protocols for the management of retinal diseases provides the potential to enhance visual acuity outcomes, reduce treatment burden, and improve patient quality-of-life measures when incorporated into practice. Emerging therapies with novel mechanisms of action or methods for delivery are also showing promise for the advancement of patient outcomes. Keeping abreast of these advances along with optimally incorporating them into everyday practice can be a challenge. In this publication series, expert retina specialists will discuss recent innovations and new technologies in imaging for diagnosis and disease monitoring; evaluate new technologies, devices, and techniques to enhance outcomes from vitreoretinal surgery; and assess the latest findings on safety and efficacy of current, new, and emerging therapies for optimal medical treatment of retinal diseases.

Target Audience

The intended audience for this educational series is retina specialists and other health care professionals involved in the management of patients with retinal diseases.

Learning Objectives

Upon successful completion of this publication series, participants should be better able to:

  • Review recent innovations in imaging for the diagnosis and monitoring of retinal diseases.
  • Evaluate new technology and imaging techniques used to monitor the treatment of patients with retinal diseases.
  • Assess the evidence on safety and efficacy to optimize the use of conventional, new, and emerging medical treatments for retinal diseases.
  • Evaluate new technology, devices, and techniques that may improve outcomes in patients undergoing vitreoretinal surgery.

Chief Medical Editor

Rishi P. Singh, MD*
Staff Physician, Cole Eye Institute
Medical Director, Clinical Systems Office
Cleveland Clinic
Associate Professor of Ophthalmology
Case Western Reserve University
Cleveland, OH

Editorial Board

David Eichenbaum, MD*
Director of Research
Retina Vitreous Associates of Florida
Collaborative Associate Professor
Morsani College of Medicine
University of South Florida
St. Petersburg, FL

Carl D. Regillo, MD, FACS*
Director, Wills Eye Retina Service
Professor of Ophthalmology
Thomas Jefferson University
Mid Atlantic Retina
Philadelphia, PA

Charles C. Wykoff, MD, PhD*
Retina Consultants of Houston
Retina Consultants of America
Blanton Eye Institute
Houston Methodist Hospital
Houston, TX

* Faculty Contributor also for this issue.

Medical Writer

Valerie Zimmerman, PhD

The articles in this monograph were composed by Medical Writer Valerie Zimmerman, PhD, based on the presentations of Drs. Eichenbaum, Regillo, Wykoff, and Singh during a virtual expert panel discussion held on July 8, 2020. The monograph has been approved by each of the faculty individually as an accurate representation of their presentations.


Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP


Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation

Vindico Medical Education designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to satisfy the Lifelong Learning requirements for the American Board of Ophthalmology’s Maintenance of Certification (ABO MOC) program. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting MOC credit. 

Upon successful completion, learners who opt-in by providing their ABO ID and DOB (MM/DD) will earn MOC credits equivalent to the amount of CME credits claimed for the activity. The CME activity provider will submit learner completion information to the ACCME for the purpose of granting ABO MOC credits within 30 days of activity completion.

This enduring material is approved for 1 year from the date of original release, October 1, 2020, through October 1, 2021.

How to Participate in This Activity and Obtain CME Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for the question. A satisfactory score is defined as answering 7 of 10 posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.


In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information appears below.

Chief Medical Editor and Editorial Board report the following relationship(s)

David Eichenbaum, MD
Consulting Fee: Alimera, Allergan, Clearside, Dutch Ophthalmic, EyePoint, Genentech, Gyroscope, Kodiak, Notal Vision, Novartis, RecensMedical, Regeneron
Speakers Bureau: Allergan, Dutch Ophthalmic, Genentech, Novartis
Contracted Research: Alimera, Allergan, Chengdu Kanghong, Clearside, Genentech, Gyroscope, Kodiak, Mylan, NGM Biopharmaceuticals, Ophthotech/Iveric Bio
Ownership Interest: Boston Image Reading Center, Clearside, Hemera Biopharmaceuticals, Network Eye

Carl D. Regillo, MD, FACS
Consulting Fee: Adverum, Allergan, Chengdu Kanghong, Genentech, Graybug Vision, Kodiak, Merck, Notal Vision, Novartis, Takeda
Contracted Research: Adverum, Allergan, Chengdu Kanghong, Genentech, Graybug Vision, Kodiak, Notal Vision, Novartis, Regeneron, Regenxbio

Rishi P. Singh, MD
Consulting Fee: Alcon, Bausch + Lomb, Genentech, Novartis, Regeneron, Zeiss
Contracted Research: Aerie, Apellis, Graybug Vision

Charles C. Wykoff, MD, PhD
Consulting Fee: Acucela, Adverum, Alimera, Allegro, Allergan, Apellis, Bayer, Chengdu Kanghong, Clearside, DORC, EyePoint, Genentech/Roche, Iveric Bio, Kodiak, Merck, Neurotech, Novartis, ONL Therapeutics, Oxurion, PolyPhotonix, Recens Medical, Regeneron, Regenxbio
Speakers Bureau: Regeneron
Contracted Research: Adverum, Aerie, Allergan, Apellis, Chengdu Kanghong, Clearside, Gemini Therapeutics, Genentech/Roche, Graybug Vision, Ionis Pharmaceuticals, Iveric Bio, Kodiak, Neurotech, Novartis, Opthea, Optos, Outlook Therapeutics, Recens Medical, Regeneron, Regenxbio, Samsung, Santen

Medical Writer reports the following relationship(s)

Valerie Zimmerman, PhD
No relevant financial relationships to disclose.

Reviewer reports the following relationship(s)

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.

Vindico Medical Education staff report the following relationship(s)

No relevant financial relationships to disclose.

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at